Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

OncoMed Pharmaceuticals Inc to Sell 4 Million Shares in IPO-DJ


Wednesday, 3 Jul 2013 06:42am EDT 

Dow Jones reported that OncoMed Pharmaceuticals Inc expects to sell 4 million common shares in its initial public offering. The development-stage biopharmaceutical company first filed plans for an estimated IPO of up to $115 million in May 2012 to fund research and drug discovery activities, working capital and general corporate expenses. The estimated size of the offering is used to set the registration fee and could change materially as the offer progresses. OncoMed is focused on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells. OncoMed has applied to list on the Nasdaq Global Market under the symbol OMED. 

Company Quote

21.48
0.3 +1.42%
19 Dec 2014